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Summary 
Retroviral vectors were the first virus vectors to be used in gene therapy trials and have proved to be successful for 
the treatment of X-linked severe combined immunodeficiency. However, there are safety concerns associated with 
the use of retroviral vectors or indeed delivery systems based upon viruses in general. Over the last few years, we 
have been developing retroviral vectors with the aim of (i) removing the retroviral promoter in transduced cells (ii) 
obtaining  limited  expression  of  therapeutic  genes  in  therapeutically  relevant  cells  by  the  inclusion  of  targeting 
promoters in place of the retroviral promoter (iii) being able to stably produce retroviral vectors carrying toxic 
genes from cells. Two of these vector systems, promoter conversion vectors and reconstituting vectors, have been 
described in proof of principle studies, but suffered from reduced titres that precluded their effective use in the 
clinic. A number of vector optimisation modifications have been made to these vectors, resulting in the successful 
improvement of both titre and expression levels such that these vectors are now suitable for use in clinical trials. 
The use of such optimised vectors for in vitro and in vivo applications using a number of different genes of interest 
will be described. Future successful gene therapy of solid tumours may require the use of replicating vectors. The 
application  of  many  of  the  principles  learned  from  the  vector  optimisation  modifications  described  above  to 
replicating MLV and MMTV based vectors will be described along with data demonstrating efficient tissue specific 
expression targeting. 
 
 
I. Introduction 
Retroviral  vectors  have  delivered  some  of  the  first 
promising  successes  in  gene  therapy,  such  as  the 
successful gene therapeutic treatment of severe combined 
immunodeficiency (Cavazzana-Calvo et al, 2000) and yet 
this success has been bittersweet since it was accompanied 
by  the  confirmation  that  retroviruses  also  have  the 
potential  to  play  a  role  in  the  series  of  events  that 
culminate in tumorigenesis in humans (Hacein-Bey-Abina 
et al, 2003a). 
The  ability  to  redesign  such  vectors  so  that  they 
specifically target therapeutically relevant cells has  long 
been an aim of gene therapists since it was realised early 
on that this would increase both the efficacy as well as the 
safety  of  gene  transfer  (Salmons  and  Günzburg,  1993; 
Weber et al, 2001). Virus vectors can either be modified 
so that they are preferentially able to infect particular cell 
types (infection targeting) or so that the gene of interest is 
expressed only in therapeutically relevant cells (expression 
targeting). While infection targeting has been shown to be 
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strategies,  it  is  invariably  associated  with  drastic 
reductions  in infection  and  thus gene  transfer efficiency 
(Karavanas  et  al,  1998).  Another  means  to  achieve  the 
targeted production of a therapeutic product is to express it 
from a tissue specific promoter and there have been many 
strategies  employed  to  create  such  expression  targeted 
retroviruses.    Over  the  last  decade,  we  have  been 
developing  retroviral  vectors  that  allow  expression 
targeting, but that also replace the virus promoter with the 
targeting  promoter  in  the  infected  cell.  This  is  an 
important feature since (i) the virus promoter often over-
rides or  inactivates  the tissue specific promoter  in other 
types of expression targeted vectors and (ii) it contributes 
to safety since the virus promoter has the potential to play 
a role in tumorigenesis (Hacein-Bey-Abina et al, 2003b) 
and  its  removal  reduces  the  chances  for  recombination 
occurring  that  might  generate  a  replication  competent 
vector. 
 
II. Promoter conversion vectors based 
on murine leukaemia virus 
Promoter  conversion  (ProCon)  vectors  utilise  the 
characteristics  of  the  natural  and  reproducible  genetic 
reshuffling  that  retroviruses  must  go  through  during  the 
process  of  reverse  transcription.  Retroviruses  are  RNA 
viruses  that  have  to  replicate  via  a  DNA.  The  virus 
encoded  reverse  transcriptase  that  creates  the  double 
stranded  DNA  form  of  the  genome  from  the  single 
stranded  virus  genomic  RNA.  The  promoter  conversion 
ProCon vectors that we have been developing utilise the 
reverse  transcriptase  mediated  genetic  reorganisation  to 
replace the virus promoter, which is active in the vector 
producing  (i.e.  packaging)  cells,  with  a  heterologous 
promoter in the vector transduced cell. If this heterologous 
promoter is preferentially expressed in a given cell type, it 
is expected that expression of the therapeutic gene carried 
by the vector will be limited to the very same cells (Figure 
1). Proof of concept for ProCon vectors has been obtained 
using murine leukaemia virus (MLV) vectors carrying a 
variety  of  nonhomologous  promoters,  i.e.  constitutively 
active  promoters  like  the  cytomegalovirus  (CMV) 
promoter or tissue specific/restrictive promoters like that 
of mouse mammary tumour virus (Saller et al, 1998) or 
whey acidic protein (Özturk-Winder et al, 2002; Lipnik et 
al,  2005).  Inducible  promoters  are  also  useful  in  this 
context  since  they  allow  cells  transduced  with  genes 
encoding proteins that are not compatible with cell growth 
to be obtained in the absence of the inducer (Mrochen et 
al, 1997). The ProCon strategy can be applied in principle 
to all retroviral and lentiviral vectors. 
 
 
Figure 1. The promoter conversion (ProCon) principle. The U3 region carried in the 3’ LTR of the retroviral vector is removed (except 
for the inverted repeated required for integration) and replaced with a promoter of choice (shaded box). The vector is then introduced 
into retroviral vector packaging cells and produces a packageable transcript. Target cells are then transduced with the vector, resulting in 
reverse transcription of the packaged RNA into a double-stranded proviral DNA. During reverse transcription, the promoter of choice, 
originally located at the 3’ end of the retroviral genomic transcript is duplicated and one copy placed at the 5’end of the virus. The 
provirus is then integrated into the host cell genome by the virus enzyme integrase. Gene Therapy and Molecular Biology Vol 10, page 187 
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Although such MCV based ProCon vectors function 
as expected, the titres of vector obtained are reduced ~100 
fold  as  compared  to  nonmodified,  first  generation  type 
MLV  vectors.  While  these  titres  are  still  useful  in  cell 
culture  experiments,  they  preclude  use  in  the  clinic.  A 
second  drawback  to  the  use  of  retroviral  vectors  based 
upon  MLV,  regardless  of  whether  they  are  of  the  first 
generation or ProCon type, is that the level of expression 
in the infected cell is not always optimal. This depends on 
the activity of the promoter that drives expression in the 
particular cell type of therapeutic relevance and can affect 
both first generation and ProCon vectors. Promoters that 
are  preferentially  active  only  in  certain  cell  types 
(i.e.tissue specific promoters) are often relatively weak in 
their ability to drive gene expression. Here we highlight 
some of the modifications that can be made to vectors to 
improve both the titres and the efficacy of gene expression 
in  transduced  cells.  Moreover,  a  combination  of  these 
modifications in a single vector results in high titre vectors 
that  efficiently  express  the  delivered  transgene  to  high 
levels.  
 
A. Modifications to improve virus titre 
1.  Inclusion  of  a  strong  enhancer  in  the 
plasmid carrying the vector 
One possible reason for suboptimal titres of vector 
produced  from  packaging  cells  is  that  the  amount  of 
genomic RNA is limiting. To address this issue, we have 
introduced  a  CMV  enhancer  into  the  backbone  of  the 
vector in both orientations and nearer either to the 5’ or to 
the  3’  long  terminal  repeat  (LTR)  (Figure  2).  The 
insertion  of  the  CMV  enhancer  reproducibly  enhanced 
vector  expression  in  both  human  and  murine  packaging 
cells two fold and increased the titre of vector produced 
from  these  cells  by  two  fold  also  as  measured  by  the 
number of genome containing virions in the supernatant of 
producer cells (determined by real-time RT-PCR) or as by 
G418  resistant  colony  formation.  This  enhancement  is 
obtained regardless of the site and orientation of insertion 
of the enhancer (Hlavaty et al, 2004a). 
 
2.  Inclusion  of  an  extended  attachment  site 
and the AT stretch 
At  the  time  of  construction  of  the  first  ProCon 
vector, it was generally accepted that the terminal 13bp of 
the double stranded DNA is necessary and sufficient as a 
recognition sequence to which the virus encoded integrase 
binds in order to effect the integration of double stranded 
MLV  DNA  into  the  host  cell  genome.  Recently,  it  has 
been shown that a longer sequence is involved and so an 
additional 23bp has been included in the vector (Figure 
2). An AT rich sequence has also been identified that is 
located just upstream of the polypurine tract that affects 
the  efficiency  of  reverse  transcription  (Figure  2). 
Incorporation  of  both  sequences  resulted  in  a  2-fold 
increase  in  titre  but  no  significant  improvement  in  the 
efficiency of reverse transcription (Hlavaty et al, 2004a). 
 
3. Inclusion of a triple polyadenylation signal 
In addition to the AAUAAA sequence located 16 to 
25bp upstream of the polyadenylation site and a GU rich 
site  20-30bp  downstream  of  this  site,  some  retroviruses 
carry  an  additional  polyadenylation  signal  in  the  U3 
region.  As  a  result  of  the  vector  design,  any  regulatory 
signals carried in the U3 region are no longer present in 
the  ProCon  vector.  To  ensure  that  efficient 
polyadenylation was occurring, three copies of the SV40 
early polyadenylation signal were inserted into the 5’ end 
of the U5 region carried by the 3’LTR, resulting in a 2 fold 
increase in viral titre (Hlavaty et al, 2004a). 
 
4. Removal of procaryotic sequences from the 
vector 
The original ProCon vectors carry a bacterial origin 
of replication to facilitate the recloning of proviruses from 
infected  cells.  This  was  deemed  important  for  proof  of 
principle and further characterisation of ProCon vectors. 
However  it  could  be  shown  that  removal  of  these 
sequences results in a 2 fold improvement in vector virus 
titres. A further improvement in vector titre was obtained 
by  replacing  the  gene  that  confers  G418  resistance  to 
infected cells with the puromycin resistance gene (Hlavaty 
et al, 2004b). This confirms the data obtained by others 
(Bowtell et al, 1988; Artelt et al, 1991; Byun et al, 1996). 
 
 
 
Figure 2. Summary of modifications improving titre and expression. Schematically shown are the modifications undertaken to improve 
ProCon vectors: (1) replacement of the U3 region in the 5’ LTR with a strong, constitutively active cytomegalovirus (CMV) promoter 
(2) extension of the inverted repeat (att) recognition site for integrase (3) insertion of three copies of a heterologous polyadenylation site 
in the U5 region of the 3’LTR (4) insertion of the woodchuck post-transcriptrional regulatory element (WPRE) (5) deletion of the SV40-
neomycin resistance cassette (6) deletion of the prokaryotic origin of replication (ori). 
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B.  Modifications  to  improve  gene 
expression 
The  removal  of  prokaryotic  sequences  and  the 
replacement  of  the  neomycin  resistance  gene  with  the 
puromycin resistance gene not only improved the titres of 
ProCon  vectors  but  also  improved  expression  of  genes 
carried by these vectors by about two fold (Hlavaty et al, 
2004b). 
Some retroviruses carry sequences that facilitate the 
transport of transcripts from the nucleus of infected cells 
to the cytoplasmic compartment. The classic example of 
this is the Rev/RRE system of human immunodeficiency 
virus (HIV). Rev is a virus encoded regulatory factor that 
binds the Rev Regulatory Element (RRE) present on viral 
nonspliced, genomic as well as single spliced env coding 
transcripts  and  couples  them  to  cell  encoded  RNA 
transport proteins such as Crm-1 for efficient export out of 
the  nucleus  of  infected  cells.  The  woodchuck 
hepadnavirus also carries a posttranscriptional regulatory 
element, the WPRE, in its genome (Donello et al, 1998). 
The WPRE has already been used to improve the transport 
and  thus  expression  of  gene  delivered  by  virus  vectors 
(Zuffrey  et  al,  1999).  In  comparison  to  other  candidate 
RNA transport elements, inclusion of the WPRE element 
in ProCon vectors resulted in an up to 4 fold increase in 
expression  (Figure  2  and  Table  1).  Indeed  it  could  be 
shown  that  improvement  in  expression  levels  can  be 
obtained  regardless  of  the  site  of  introduction  of  the 
WPRE  in  the  vector  genome  (Hlavaty  et  al,  2005). 
Nevertheless,  it  should  be  noted  that  we  have  recently 
shown  the  ability  of  the  WPRE  to  improve  gene 
expression  can  be  both  promoter  and  cell  type  specific 
(Klein et al, 2006). 
Recently, a high incidence of liver tumours after in 
utero  application  of  a  third-generation  equine  infectious 
anaemia  virus  vectors  carrying  the  WPRE  has  been 
observed (Coutelle et al, 2005) and it remains to be seen if 
this finding is generally applicable to all vector types and 
configurations as well as for nonfatal gene transfer. 
 
III.  Reconstituting  vectors  based  on 
MLV 
It is difficult to establish stable, quality controllable, 
retroviral  vector  producing  cells  delivering  genes  that 
encode a toxic protein, or proteins that are not compatible 
with  cell  growth  such  as  cell  cycle  inhibitors  or  pro-
apoptotic  proteins  since  these  gene  products  preclude 
longterm growth of the vector producing cells. A popular 
strategy  to  overcome  this  difficulty  is  to  create  drug 
inducible  vector  systems.  These  are  however  always  to 
some extent leaky and it is difficult to remove the inducer 
(often  an  antibiotic  or  hormone)  from  the  final  vector 
preparation  which  may  cause  problems  or  raise  safety 
issues.  
The  reconstituting  vector  has  been  created  to 
overcome this problem. Similar to the ProCon system, the 
principle  behind  the  ReCon  system  is  based  on  the 
necessity  for  the  genomic  retroviral  RNA  to  undergo 
reverse  transcription  in  the  target  infected  cell,  thereby 
producing a provirus which then gives rise to therapeutic 
gene expression (Figure 3). The retroviral vector that is 
introduced into the producing cell line has two features: (i) 
it carries the therapeutic gene coding sequences, lacking a 
promoter,  in  the  opposite  orientation  to  the  vector 
transcription in place of the U3 region at the end of the 
transcriptional unit, which thus cannot be expressed and 
(ii)  it  carries  a  promoter  of  choice  inserted  into  the  U5 
region at the 5’ end, also in the opposite orientation to the 
vector transcription, which thus cannot drive expression in 
vector  producing  cells  (Figure  3).  The  vector  genomic 
RNA,  expressed  from  the  classic  retroviral  promoter,  is 
packaged into virions and infection of target cells with the 
vector virus can proceed as usual. After infection, the virus 
genomic  RNA  is  reverse  transcribed  and  generates  a 
double  stranded  proviral  DNA  in  which  the  coding 
sequence of the therapeutic gene is now placed in close 
proximity to the heterologous promoter thereby creating a 
functional  transcriptional  unit.  Moreover,  there  are  two 
copies  of  the  promoter-gene  expression  cassette,  one  at 
each end of the provirus, in the virus infected cell (Figure 
3).  Proof  of  principle  for  the  ReCon  vector  has  been 
obtained  using  the  enhanced  green  fluorescent  protein 
(eGFP) gene and a number of promoters (Tabotta et al, 
2001).  Genes  encoding  toxins  such  as  the  diphtheria  A 
toxin are now being tested in the ReCon system. 
 
IV.  Mouse  Mammary  Tumour  Virus 
as a retroviral vector 
As  mentioned  above,  the  mouse  mammary  tumour 
virus  (MMTV)  promoter  shows  specificity  in  that  it  is 
preferentially  active  in  mammary  epithelial  and  tumour 
cells as well as B-lymphocytes (Günzburg and Salmons, 
1992; Zhu and Dudley, 2001). Further MMTV promoter 
activity  is  inducible  by  glucocorticoid  hormones
 
Table 1. Some post-transcriptional regulatory elements that function poorly in ProCon vectors
1 
 
Element  Source  Reference 
     
constitutive transport element (CTE)  simian retrovirus type D (SRV-1)  Zhao et al, 2000 
Retroviral transport element (RTE)  endogenous retrovirus VL30 
Nappi  et  2001;  Smulevitch  et  al, 
2005 
5’ untranslated transcript region (5’UTR)   heat shock protein 70 gene 
Huez  et  al,  1998;  Vivinus  et  al, 
2005 
 
1Hlavaty et al, 2005 Gene Therapy and Molecular Biology Vol 10, page 189 
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Figure 3. The reconstituting (ReCon) vector principle. The U3 region carried in the 3’LTR of the retroviral vector is removed (except 
for the inverted repeated required for integration) and replaced with a promoterless gene of choice inserted in the opposite transcriptional 
orientation to that of the vector (shaded box). In addition, a promoter of choice is inserted into the U5 region of the 5’LTR (without 
deleting U5  sequences),  again in  the opposite transcriptional orientation  to the vector. Thus  the promoter  and gene of  interest  are 
physically separated and are not active in vector producing cells. The vector is then introduced into retroviral vector packaging cells and 
produces a packageable transcript. Target cells are then transduced with the vector, resulting in reverse transcription of the packaged 
RNA into a double-stranded proviral DNA. During reverse transcription, the promoter of choice, originally located at the 5’ end of the 
retroviral genomic transcript is duplicated and one copy placed at the 3’ end of the provirus and the gene of interest is also duplicated 
and one copy placed at the 5’ end of the provirus. Thus two reconstitute expression cassettes are generated at either end of the provirus, 
which is then integrated into the host cell genome by the virus enzyme integrase. 
 
 
(Günzburg  and  Salmons,  1992;  Aurrekoetxea-Hernandez 
and  Buetti,  2004),  shows  mammary  specificity  in 
transgenic mice (Figure 4) and, when it is inserted into a 
ProCon vector it retains both cell type specificity, at least 
in  transgenice  mice,  as  well  as  hormone  inducibility 
(Mrochen  et  al,  1997;  Saller  et  al,  1998).  MMTV  is 
thought to be poorly  infective  in  cell culture,  though in 
vivo  it  may  show  infection  specificity  for  murine 
mammary epithelial cells and other glandular cells as well 
as for B and T lymphocytes. MMTV would thus make an 
ideal  mammary/B-lymphocyte  specific  infection  and 
expression targeted vector system. However, the virus is 
poorly infectious even for mouse mammary gland cells in 
cell culture and it is reported to be poorly infectious for 
human  cells.  This  latter  observation  seemed  to  be 
supported  by  the  recent  identification  of  the  MMTV 
receptor  as  the  murine  transferrin  receptor,  since  the 
human  form  of  this  receptor  appears  to  be  either  non-
functional  (Ross  et  al,  2002)  or  only  weakly  functional 
(Zhang et al, 2003). Nevertheless, the murine transferrin 
receptor is known to be expressed on many cell types in 
vivo and so this alone cannot explain  apparent  infection 
spectrum  of  MMTV  in  vivo.  One  caveat  to  the  studies 
involved  in  the  identification  of  the  MMTV  receptor  is 
that  they  were  conducted  using  pseudotyped  vectors 
consisting  of  an  MLV  genome  carrying  the  ß-
galactosidase gene in an MLV core with the envelope of 
MMTV.  These  pseudotyped  vectors  were  generated  by 
transient  transfection. It  is conceivable  that such vectors 
do  not  accurately  mimic  the  infection  with  a  wild  type 
MMTV. In addition, only one strain of MMTV envelope 
was tested in these pseudotyped vectors whereas there are 
many MMTV variants in mice. 
We have recently shown that both wild-type MMTV 
produced from a mouse mammary tumour derived cell line 
as well as a replication competent MMTV vector carrying 
an eGFP gene can efficiently infect a number of cultured 
human cell lines including mammary tumour derived cell 
lines (Indik et al, 2005). A number of lines of evidence for 
specific, infection mediated transfer of MMTV rather than Günzburg et al: New generations of retroviral vector for safe, efficient and targeted gene therapy 
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a  non-infection  specific  transfer  have  been  provided 
(Table  2).  The  ability  of  MMTV  to  infect  human  cells 
opens  up  the  possibility  of  developing  MMTV  as  a 
mammary  tumour  and  B-lymphocyte  specific  vector  for 
use in gene therapy approaches for the treatment of human 
diseases. 
Intriguingly,  these  findings  also  strengthen 
previously  reported  observations  that  MMTV  DNA 
sequences  can  be  found  in  between  37-42%  of  human 
breast tumours (Etkind et al, 2000; Lui et al, 2001; Melana 
et al, 2001; Ford et al, 2003), 
 
 
 
Figure  4.  Transgenic  mouse  carrying  an  MMTV-eGFP 
expression  construct.  Shown  is  a  mouse  carrying  a  transgene 
consisting  of  the  MMTV  LTR  linked  to  the  eGFP  gene. 
Expression of eGFP can be  seen  specifically in  the  mammary 
glands.
 
 
Table 2. Evidence for true and specific infection of human cells by MMTV
1 
 
Action    Result 
     
Infection with:     
wild type virus   
   
specific PCR signals in infected 
human cells 
     
  eGFP carrying 
replication competent virus    eGFP expressing cells 
     
------------------------------------------------------------------------------------------------------------------- 
Pre-treatment of virus with:     
MMTV neutralising antibody    Abolishes infection 
Heat     Abolishes infection 
     
  Abolishes infection  Virus  with  premature  termination 
codon in MMTV Env     
     
---------------------------------------------------------------------------------------------------------------------- 
Sequencing of DNA from MMTV    Typical of retroviral integration: 
integration sites from host genome     - deletion of last 2bp of viral RNA 
   
   
- duplication of 5bp at site of integration 
Human specific sequences found with no 
known mouse counterparts 
 
1data from Indik et al, 2005  
 Gene Therapy and Molecular Biology Vol 10, page 191 
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thus suggesting that MMTV infection may also play a role 
in breast tumour development in women. If these findings 
are verified, then an evaluation of MMTV antigen status in 
women may become a public health issue.  
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